Add Row 
Add 
Understanding the Shift from Monotherapy in Dermatology
At the DERM 2025 conference, Dr. J. Scott Boswell emphasized a transformative approach to treating complex inflammatory skin diseases. Moving away from strict 'monotherapy brain'—the practice of relying solely on single-agent treatments—Boswell advocates for innovative combination therapies that consider the multifaceted nature of these conditions.
The Challenge of Monotherapy
Many dermatologists fall into a familiar pattern: prescribing monotherapy for patients with moderate to severe skin issues. This can often be a limitation, as these patients may not respond adequately to treatment. Instead, Boswell's insights suggest that a more nuanced approach is necessary. One of his key recommendations is to understand the underlying pathophysiology of skin diseases fully. By doing so, practitioners can select medications that target various aspects of the disease simultaneously, thus improving overall patient outcomes.
Combining Therapies for Enhanced Effectiveness
Boswell shared practical strategies for clinicians looking to embrace combination therapies. For instance, he suggests using methotrexate alongside tumor necrosis factor inhibitors to mitigate the formation of neutralizing antibodies. This not only enhances the efficacy of treatment but also provides a defense against other health risks, such as diminished COVID-19 vaccine efficacy, which is vital for patient safety.
Practical Pearls from the Conference
The conference revealed several pearls of wisdom for clinical practice:
- Combining Psoriasis and Atopic Dermatitis Biologics: While combining these therapies can be beneficial, it's important to pair them wisely. For example, existing immunosuppressive therapies for psoriasis should not be doubled up with immunosuppressive ones for atopic dermatitis. Instead, the combination of a psoriasis biologic with non-immunosuppressive agents for atopic dermatitis provides a safer and potentially more effective treatment plan.
- Topical Adjustments are Key: When a patient is experiencing a flare despite systemic treatments, revisiting topical therapies can be critical. New options like tapinarof and roflumilast offer fresh alternatives for effective symptom management.
- Utilizing NBUVB Phototherapy: When conventional systemic treatments fail, NBUVB phototherapy and targeted intralesional corticosteroid injections can help manage stubborn flare-ups.
- Specific Considerations for Comorbid Conditions: In instances where psoriasis coexists with irritable bowel syndrome, Boswell suggests using TNF inhibitors like infliximab, which can manage both conditions effectively.
The Future of Dermatological Treatments
As dermatological science advances, there's a growing recognition of the importance of individualized treatment plans. The pharmaceutical landscape is evolving, but it still requires a shift in thinking from both practitioners and patients. This broader perspective encourages the utilization of combination therapies tailored to each patient’s unique pathophysiology.
Breaking Down Barriers in Treatment Accessibility
One notable point raised during the conference was the challenge patients face when navigating insurance hurdles for biologics. Dr. Boswell’s approach to addressing these concerns highlights the importance of advocating for patients to ensure they receive necessary treatments. By effectively communicating the risks and benefits associated with these advanced therapies, healthcare providers can improve access for their patients.
Take Action: Embrace Combination Therapies
The evolution of skin disease treatment underscores a pivotal moment in dermatology that emphasizes a holistic, evidence-based approach. By considering combination therapies and advocating for patient access to advanced treatments, practitioners can navigate the complexities of skin diseases more effectively. This proactive stance not only leads to better patient outcomes but also fosters a deeper understanding of dermatological health.
Write A Comment